TABLE 1.
Clinical and Pathologic Characteristics
| Parameter | Black, n (%) (n=666) |
White, n (%) (n=666) |
p-value |
|---|---|---|---|
| Mode of diagnosis | 0.446 | ||
| Mammogram | 255 (38.3%) | 298 (44.7%) | |
| Ultrasound | 5 (0.8%) | 17 (2.6%) | |
| MRI | 5 (0.8%) | 13 (2%) | |
| Physical findings | 287 (43.1%) | 304 (45.6%) | |
| Incidental | 0 (0) | 7 (1.1%) | |
| Missing | 114 (17.1%) | 27 (4.1%) | |
| Insurance | |||
| Government | 348 (52.3%) | 291 (43.7%) | <0.001 |
| Commercial/Private | 318 (47.7%) | 375 (56.3%) | |
| Address | |||
| Manhattan | 69 (10.4%) | 66 (10%) | |
| Brooklyn | 201 (30.3%) | 46 (6.9%) | <0.001 |
| Queens | 90 (13.6%) | 44 (6.6%) | |
| Bronx | 73 (11%) | 8 (1.2%) | |
| Other New York | 118 (17.8%) | 233 (35.2%) | |
| New Jersey | 53 (8%) | 159 (24%) | |
| Other state | 60 (9%) | 106 (16%) | |
| Missing | 2 (0.3%) | 4 (0.6%) | |
| Tumor size (cm) | 1.6 (0.1, 15.5) | 1.3 (0, 11) | <0.001 |
| AJCC Stage | <0.001 | ||
| Stage I | 311 (46.7%) | 395 (59.3%) | |
| Stage II | 226 (33.9%) | 179 (26.9%) | |
| Stage III | 105 (15.8%) | 69 (10.4%) | |
| NA | 24 (3.6%) | 23 (3.5%) | |
| ER | <0.001 | ||
| Negative | 219 (32.9%) | 100 (15%) | |
| Positive | 442 (66.4%) | 560 (84.1%) | |
| NA | 5 (0.8%) | 6 (0.9%) | |
| PR | <0.001 | ||
| Negative | 314 (47.1%) | 201 (30.2%) | |
| Positive | 345 (51.8%) | 458 (68.8%) | |
| NA | 7 (1.1%) | 7 (1.1%) | |
| HER2 | 0.878 | ||
| Equivocal | 9 (1.4%) | 2 (0.3%) | |
| Negative | 526 (79%) | 542 (81.4%) | |
| Positive | 106 (15.9%) | 95 (14.3%) | |
| NA | 25 (3.8%) | 27 (4.1%) | |
| Grade (Histological) | 0.949 | ||
| 1 | 25 (3.8%) | 79 (11.9%) | |
| 2 | 109 (16.4%) | 172 (25.8%) | |
| 3 | 446 (67%) | 361 (54.2%) | |
| NA | 86 (12.9%) | 54 (8.1%) | |
| Grade (Nuclear) | <0.001 | ||
| Low | 14 (2.1%) | 62 (9.3%) | |
| Intermediate | 186 (27.9%) | 252 (37.8%) | |
| High | 290 (43.5%) | 207 (31.1%) | |
| NA | 176 (26.4%) | 145 (21.8%) | |
| Nodal Status | <0.001 | ||
| Negative | 390 (58.6%) | 444 (66.7%) | |
| Positive | 274 (41.1%) | 213 (32%) | |
| NA | 2 (0.3%) | 9 (1.4%) | |
| ECE | 0.115 | ||
| No | 523 (78.5%) | 572 (85.9%) | |
| Yes | 102 (15.3%) | 87 (13.1%) | |
| NA | 41 (6.2%) | 7 (1.1%) | |
| LVI | 0.598 | ||
| No | 439 (65.9%) | 463 (69.5%) | |
| Yes | 202 (30.3%) | 200 (30%) | |
| NA | 25 (3.8%) | 3 (0.5%) | |
| Molecular Subtype | <0.001 | ||
| HR−/HER2− | 160 (24%) | 59 (8.9%) | |
| HR−/HER2+ | 45 (6.8%) | 30 (4.5%) | |
| HR+/HER2− | 366 (55%) | 483 (72.5%) | |
| HR+/HER2+ | 61 (9.2) | 64 (9.6%) | |
| NA | 34 (5.1%) | 30 (4.5%) |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; NA, not available; ECE, extracapsular extension; LVI, lymphovascular invasion; HR, hormone receptor